Cancer immunotherapy: moving beyond current vaccines
- PMID: 15340416
- PMCID: PMC1435696
- DOI: 10.1038/nm1100
Cancer immunotherapy: moving beyond current vaccines
Abstract
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
Comment in
-
Cancer vaccines: pessimism in check.Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80. doi: 10.1038/nm1204-1278. Nat Med. 2004. PMID: 15580242 No abstract available.
-
Cancer vaccines: pessimism in check.Nat Med. 2004 Dec;10(12):1279; author reply 1279-80. doi: 10.1038/nm1204-1279a. Nat Med. 2004. PMID: 15682512 No abstract available.
References
-
- Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–384. - PubMed
-
- Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:876–886. - PubMed
-
- Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415–2432. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
